MannKind To Pay $23M In Investor Suit Over Diabetes Drug

By Zach Winnick (September 10, 2012, 5:09 PM EDT) -- A California judge on Monday preliminarily approved MannKind Corp.'s $23 million securities class action settlement with shareholders who claim the pharmaceutical company misled them about the regulatory approval prospects of its diabetes drug Afrezza, allegedly causing up to $158 million in investor losses....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!